Intersect ENT Inc  

(Public, NASDAQ:XENT)   Watch this stock  
Find more results for William G. Kaufman�
+0.30 (1.50%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.65 - 20.47
52 week 15.53 - 32.85
Open 20.08
Vol / Avg. 141,844.00/514,908.00
Mkt cap 559.98M
P/E     -
Div/yield     -
EPS -0.96
Shares 28.01M
Beta     -
Inst. own 107%
Feb 24, 2016
Q4 2015 Intersect ENT Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 1, 2015
Intersect ENT Inc at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Nov 19, 2015
Intersect ENT Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 4, 2015
Q3 2015 Intersect ENT Inc Earnings Call
Nov 4, 2015
Q3 2015 Intersect ENT Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -68.42% -47.59%
Operating margin -69.31% -46.85%
EBITD margin - -45.34%
Return on average assets -25.90% -43.73%
Return on average equity -28.38% -
Employees 266 -
CDP Score - -


1555 Adams Dr
MENLO PARK, CA 94025-1439
United States - Map
+1-650-6412100 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat conditions. The Company's commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products, RESOLVE and NOVA, for treatment of patients in the physician's office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA, a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.

Officers and directors

Lisa D. Earnhardt President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Jeryl L. Hilleman Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Richard E Kaufman Senior Vice President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
James Stambaugh Vice President of Clinical and Reimbursement
Age: 45
Bio & Compensation  - Reuters
Amy Conuel Wolbeck Vice President of Regulatory Affairs and Quality
Age: 42
Bio & Compensation  - Reuters
Chas S. McKhann Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Kieran T. Gallahue Lead Director
Age: 51
Bio & Compensation  - Reuters
William Anthony Vernon Director
Age: 59
Bio & Compensation  - Reuters
Cynthia L. Lucchese Independent Director
Age: 54
Bio & Compensation  - Reuters
Dana G Mead Jr. Independent Director
Age: 56
Bio & Compensation  - Reuters